tiprankstipranks
Reata downgraded to Market Perform from Outperform at SVB Securities
The Fly

Reata downgraded to Market Perform from Outperform at SVB Securities

SVB Securities downgraded Reata Pharmaceuticals (RETA) to Market Perform from Outperform with a price target of $172.50, up from $115, after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on RETA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles